Flunisolide nasal spray 0.025% in the prophylactic treatment of nasal polyposis after polypectomy. A randomized, double blind, parallel, placebo controlled study.

Paper

Flunisolide nasal spray 0.025% in the prophylactic treatment of nasal polyposis after polypectomy. A randomized, double blind, parallel, placebo controlled study.

Published Mar 1, 1985 · G. Dingsør, J. Kramer, R. Olsholt

Rhinology

Q1 SJR score

84

Citations

1

Influential Citations

Semantic Scholar

Abstract

This double blind, parallel study compared flunisolide 2 X 25 mcg in each nostril twice daily, with placebo in the prophylaxis of nasal polyposis recurrence after surgery. The treatment lasted for 12 months. The study was conducted according to the recommendations of the Declaration of Helsinki, and the patients gave verbal consent to participate. The study was reviewed by the Norwegian Medicines Control Authority. Forty-one patients with first or recurrent polypectomy were enrolled. Thirty-seven patients completed the 12 months' period. Four patients dropped out prematurely for reasons unrelated to the test drug. Flunisolide was significantly superior to placebo in preventing recurrence of polyps during 6 to 12 months' treatment, both with respect to number (p = 0.05) and size (p = 0.03) of polyps. Nasal symptoms of sneezing and stuffiness decreased significantly for flunisolide treated patients during treatment. In the placebo group, there was a significant increase in stuffiness throughout the year. For runny nose, there was no difference between the treatments. Six flunisolide patients and 10 placebo patients reported side effects during the one year treatment, transient mild itching being the most common complaint. Three cases of secretion with bloody traces were reported. No patient withdrew for drug related reasons. In this study, flunisolide was significantly more effective than placebo in preventing recurrence of nasal polyposis during one year's treatment after polypectomy.

RCT

Highly Cited

Study Snapshot

Flunisolide nasal spray 0.025% effectively prevents nasal polyposis recurrence during one year's treatment after polypectomy, with minimal side effects.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Sign up to use Study Snapshot

Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.

Create an account

Paper

Flunisolide nasal spray 0.025% in the prophylactic treatment of nasal polyposis after polypectomy. A randomized, double blind, parallel, placebo controlled study.

Sign up to use Study Snapshot

References

Citations

Intrapolyp Steroid Injection for Nasal Polyposis: A Systematic Review and Network Meta-Analysis.

Intrapolyp steroid injections show a favorable safety and efficacy profile as a viable management option for chronic rhinosinusitis with nasal polyps, showing comparable efficacy to oral steroids and advantages over nasal sprays and washes.

The role of budesonide intrapolyp injection in the management of type 2 chronic rhinosinusitis with nasal polyps: a randomised clinical trial

Budesonide intrapolyp injection is an effective and safe treatment for chronic rhinosinusitis with nasal polyps, with comparable results to oral steroids.

Therapeutic Strategies to Prevent the Recurrence of Nasal Polyps after Surgical Treatment: An Update and In Vitro Study on Growth Inhibition of Fibroblasts

Diclofenac effectively inhibits fibroblast proliferation, potentially preventing nasal polyp recurrence after surgical treatment for chronic rhinosinusitis with nasal polyps.

Mucin receptors in chronic rhinosinusitis with nasal polyps

MUC5A receptor positivity in chronic rhinosinusitis with nasal polyps is associated with impaired surgical site quality and reduced response to low-dose systemic steroids.

International consensus statement on allergy and rhinology: rhinosinusitis 2021

The ICAR-RS-2021 document reflects progress in understanding and treating rhinologic diseases, covering more than 40 new topics and updating 140 original topics.